Payment overview · 2025
General Payments
$113.52
6 reported records · 4 companies
Healthcare provider profile · identity verified
Lorena Sousa, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PORT ST LUCIE, FL · NPI 1679000756
Verified facts
What the public records show
CMS Open Payments records show Lorena Sousa, MD received $113.52 in general payments during 2025 across 6 reported records.
AstraZeneca Pharmaceuticals LP accounted for 36.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $41.55 | 36.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.59 | 26.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.53 | 20.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 16.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $94.67 | 5 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 174 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 98 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
61 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
98 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
174 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 555 | 174 |
| Amlodipine Besylate | Amlodipine Besylate | 440 | 131 |
| Lisinopril | Lisinopril | 376 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 342 | 94 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 323 | 75 |
| Omeprazole | Omeprazole | 269 | 74 |
| Losartan Potassium | Losartan Potassium | 263 | 87 |
| Metformin Hcl | Metformin Hcl | 229 | 72 |
| Gabapentin | Gabapentin | 197 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 180 | 60 |
| Eliquis | Apixaban | 174 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 163 | 54 |
| Trazodone Hcl | Trazodone Hcl | 163 | 50 |
| Furosemide | Furosemide | 157 | 61 |
| Ozempic | Semaglutide | 148 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 138 | 49 |
| Montelukast Sodium | Montelukast Sodium | 135 | 33 |
| Carvedilol | Carvedilol | 126 | 41 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 126 | 53 |
| Simvastatin | Simvastatin | 124 | 35 |
| Alprazolam | Alprazolam | 121 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 121 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 49 |
| Jardiance | Empagliflozin | 98 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 34 |
| Potassium Chloride | Potassium Chloride | 91 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 29 |
| Sertraline Hcl | Sertraline Hcl | 84 | 26 |
| Alendronate Sodium | Alendronate Sodium | 76 | 25 |
| Glipizide | Glipizide | 76 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 76 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 19 |
| Famotidine | Famotidine | 74 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 70 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 22 |
| Lorazepam | Lorazepam | 66 | suppressed |
| Ezetimibe | Ezetimibe | 64 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 61 | 14 |
| Clonidine Hcl | Clonidine Hcl | 57 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | suppressed |
| Nifedipine Er | Nifedipine | 50 | 14 |
| Atenolol | Atenolol | 49 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 48 | suppressed |
| Diazepam | Diazepam | 48 | suppressed |
| Clonazepam | Clonazepam | 46 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 16 |
| Pregabalin | Pregabalin | 44 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 44 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | suppressed |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 11 |
| Celecoxib | Celecoxib | 42 | 13 |
| Ondansetron Odt | Ondansetron | 42 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 12 |
| Meloxicam | Meloxicam | 41 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 35 |
| Tramadol Hcl | Tramadol Hcl | 41 | 18 |
| Allopurinol | Allopurinol | 40 | 12 |
| Enalapril Maleate | Enalapril Maleate | 40 | 12 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | suppressed |
| Rybelsus | Semaglutide | 38 | 11 |
| Topiramate | Topiramate | 38 | 11 |
| Ibuprofen | Ibuprofen | 37 | 16 |
| Glimepiride | Glimepiride | 35 | 13 |
| Valacyclovir | Valacyclovir Hcl | 35 | suppressed |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Temazepam | Temazepam | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 18 |
| Lovastatin | Lovastatin | 30 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 25 |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | 11 |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | 11 |
| Trulicity | Dulaglutide | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Prednisone | Prednisone | 23 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | 13 |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Indomethacin | Indomethacin | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Nystatin | Nystatin | 15 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $113.52 · 6 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, JARDIANCE, NURTEC ODT, PREVNAR 20 | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error